.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
AstraZeneca
US Department of Justice
Queensland Health
Argus Health
Harvard Business School
Healthtrust
Julphar
Johnson and Johnson
Express Scripts

Generated: June 26, 2017

DrugPatentWatch Database Preview

Sevelamer hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for sevelamer hydrochloride and what is the scope of sevelamer hydrochloride patent protection?

Sevelamer hydrochloride
is the generic ingredient in one branded drug marketed by Genzyme and is included in two NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Sevelamer hydrochloride has thirty-eight patent family members in thirty-one countries.

There are thirty-two drug master file entries for sevelamer hydrochloride. Five suppliers are listed for this compound.

Summary for Generic Name: sevelamer hydrochloride

Tradenames:1
Patents:2
Applicants:1
NDAs:2
Drug Master File Entries: see list32
Suppliers / Packagers: see list5
Bulk Api Vendors: see list26
Clinical Trials: see list2,297
Therapeutic Class:Genitourinary Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:sevelamer hydrochloride at DailyMed

Pharmacology for Ingredient: sevelamer hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme
RENAGEL
sevelamer hydrochloride
TABLET;ORAL021179-002Jul 12, 2000RXYesYes6,733,780► SubscribeY ► Subscribe
Genzyme
RENAGEL
sevelamer hydrochloride
CAPSULE;ORAL020926-001Oct 30, 1998DISCNNoNo► Subscribe► Subscribe
Genzyme
RENAGEL
sevelamer hydrochloride
TABLET;ORAL021179-001Jul 12, 2000RXYesNo6,733,780► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: sevelamer hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme
RENAGEL
sevelamer hydrochloride
TABLET;ORAL021179-001Jul 12, 20005,496,545► Subscribe
Genzyme
RENAGEL
sevelamer hydrochloride
TABLET;ORAL021179-002Jul 12, 20006,509,013► Subscribe
Genzyme
RENAGEL
sevelamer hydrochloride
TABLET;ORAL021179-001Jul 12, 20006,509,013► Subscribe
Genzyme
RENAGEL
sevelamer hydrochloride
CAPSULE;ORAL020926-001Oct 30, 19985,496,545► Subscribe
Genzyme
RENAGEL
sevelamer hydrochloride
CAPSULE;ORAL020926-001Oct 30, 19986,509,013► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: sevelamer hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,187,631Direct compression polymer tablet core► Subscribe
9,579,343Direct compression polymer tablet core► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: sevelamer hydrochloride

Country Document Number Estimated Expiration
China1382041► Subscribe
Austria286386► Subscribe
Bulgaria106626► Subscribe
Denmark1239837► Subscribe
Japan2012067132► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SEVELAMER HYDROCHLORIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/011United Kingdom► SubscribePRODUCT NAME: SEVELAMER; REGISTERED: UK EU/1/99/120/001-004 20000202
0716606/01Switzerland► SubscribePRODUCT NAME: SEVELAMER; REGISTRATION NUMBER/DATE: SWISSMEDIC 56297 10.02.2004
/2009Austria► SubscribePRODUCT NAME: SEVELAMERCARBONAT; REGISTRATION NO/DATE: EU/1/09/521/001- EU/1/09/521/007 20090610
C0011France► SubscribePRODUCT NAME: SEVELAMER; REGISTRATION NO/DATE: EU/1/99/123/001 20000128
00080Netherlands► SubscribePRODUCT NAME: SEVELAMER, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SEVELAMER HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/99/123/001-00420000128 20000128
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Queensland Health
Merck
Farmers Insurance
Argus Health
Federal Trade Commission
Daiichi Sankyo
Medtronic
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot